A global dermatology experts’ team recently released guidelines for Hidradenitis suppurativa (HS) for the foremost time in North America. Reportedly, these guidelines will help in the diagnosis and management of HS—a debilitating and critical skin disease. Currently, there is no certain treatment available for this disease. The research team included dermatology experts from Henry Ford Hospital, Detroit.
Although HS is a noncontiguous disease, patients suffering from this disease are seen developing painful bumps, blackheads, or huge abscesses in the groin, armpits, genital areas, and under the breasts. The disease affects mental health, socioeconomic status, and quality of life of an individual. Approximately 1–4% of the worldwide population is affected by this disease.
For years, HS was either underdiagnosed or misdiagnosed. The latest facts-based guidelines—open for nurses, doctors, and other health practitioners—can be accessed in the Journal of the American Academy of Dermatology. These guidelines will offer all healthcare providers with a roadmap in the identification and treatment of HS. However, according to the authors, these guidelines are not intended for the establishment of a standard of care. They highlight that HS patients should be offered care under the guidance of their physician. They also emphasized that numerous factors distinctive to individual patients should be considered before HS patients treatment.
Available in two parts, Part One of HS guidelines describes the diagnosis, epidemiology, pain management strategies, and surgical treatment options for HS. Similarly, suggested antibiotics, topical medicines, and biologic therapies are covered in Part Two. These guidelines were crafted with the help from Angela Miller and Iltefat Hamzavi.
On a similar note, a research team at the Brown University highlighted the link between the lower risk of squamous cell carcinoma—a widespread skin cancer—and the dietary intake of vitamin A from plant sources. Mostly, fair-skinned individuals are more prone to develop squamous cell carcinoma, which is the second widespread skin carcinoma.